Bayer shares climbed about 1.5% shortly after the open on Tuesday to their highest level since May 2023, after the US Food and Drug Administration approved Sunharbo (asundexian), the first Factor XIa inhibitor approved in the US. In its main trial the once-daily pill cut repeat ischemic strokes by 26% with similar rates of major bleeding, and one analyst said the risk to Bayer's drug pipeline had fallen significantly.
The gain extends a strong run. Bayer was already the best performer in Germany's DAX this year, up about 55% since January, according to dpa-AFX. The shares closed last week at €55.58 after rising 15.01% in the week to 30 October and 9.89% in the week to 6 November, a two-week gain of about 26%.
Sunharbo in numbers
- 26% fewer ischemic strokes in the OCEANIC-STROKE trial
- 12,327 patients in the Phase III study
- $748.50 US list price for a 30-day supply
What the FDA Approved
Bayer announced the decision late on Monday, US time. Sunharbo is a 50mg tablet taken once a day together with antiplatelet therapy. It is approved to reduce the risk of stroke in adults who have recently had a non-cardioembolic ischemic stroke, one not caused by a clot travelling from the heart, or a high-risk transient ischemic attack.
The FDA reviewed the application under Priority Review. China's regulator approved the drug in October, and applications in other markets are under review.
Bayer expects to start shipping in November, with hospitals and pharmacies able to order soon after. The list price is $748.50 for a 30-day supply, although Bayer says actual costs vary by health plan and coverage.
Bayer: share price, chart and news

The Trial Behind the Decision
The approval rests on OCEANIC-STROKE, a Phase III study that randomised 12,327 patients and was published in the New England Journal of Medicine. Adding asundexian to standard antiplatelet therapy cut ischemic strokes by 26% compared with antiplatelet therapy alone. TCTMD, a cardiology news service, reported an absolute reduction of 2.2 percentage points over two years of follow-up.
Major bleeding, the main concern with any blood thinner, ran at similar rates in both groups. Gastrointestinal bleeding ran at 2.7 events per 100 patient-years on asundexian against 2.1 on placebo. Some patients showed raised liver enzymes, about three quarters of those cases mild, according to Bayer.
The medical need is large. Bayer puts the number of strokes worldwide at about 12 million a year, and says roughly one in ten survivors of a non-cardioembolic ischemic stroke has another within a year.
Why Investors Care
Analysts treated the approval as a removal of risk rather than a surprise. Jefferies analyst Michael Leuchten, who rates the stock Neutral, said the US approval had been expected but that the risk to the pharma pipeline had fallen significantly. Bank of America kept its Buy rating and pointed to a good label, while Deutsche Bank Research raised its price target and kept a Buy rating.
dpa-AFX described the drug as the successor to Xarelto, Bayer's former blockbuster blood thinner, in stroke prevention. Replacing that income is central to the investment case for the pharmaceuticals division.
The approval arrives a week after Bayer lifted its 2026 guidance. On 3 November it raised its target for adjusted core earnings to €9.8bn to €10.3bn, from €9.6bn to €10.1bn, after third-quarter pharma sales of €4.68bn came in about 5% above analysts' forecasts in a Vara Research poll, Reuters reported. It also cut its expected net financial debt by €1bn, to €28bn to €29bn, and the shares rose about 5% that morning. Earlier, positive rulings in the US glyphosate litigation had already lifted the stock, dpa-AFX said.
What Comes Next
Uptake is the first test. Cheryl Bushnell of Wake Forest University School of Medicine told TCTMD that cost is likely to be the main limit on how widely the drug is used.
The second is the rest of the world, where Bayer's applications in other markets are still under review.
The third is the Roundup litigation. Bayer is waiting for a Missouri state court judge in St. Louis to rule on its proposed $7.25bn settlement of US claims over the weedkiller. Chief executive Bill Anderson said on 3 November that he expected approval before Christmas: "It could be any week now."
Sources
- MarketScreener (Bayer release): Bayer's asundexian first FXIa inhibitor approved by U.S. Food and Drug Administration for secondary stroke risk reduction
- MarketScreener (dpa-AFX): Bayer remains in demand after US approval
- TCTMD: Asundexian Is the First Factor XIa Inhibitor to Gain FDA Approval
- Pharmaceutical Executive: FDA approves asundexian for secondary stroke risk reduction
- SRN News (Reuters): Bayer hikes 2026 profit outlook as pharma unit beats expectations
- BMK News market data (delayed exchange data)







